Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.